期刊
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
卷 53, 期 7, 页码 547-561出版社
OXFORD UNIV PRESS
DOI: 10.1093/jjco/hyad052
关键词
lung cancer; EGF receptor; tyrosine kinase inhibitors; precision medicine
类别
Osimertinib is the standard therapy for EGFR-mutated non-small cell lung cancer, but resistance is a challenge, leading to the need for new therapeutic strategies.
Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study. However, resistance inevitably hinders patient prognosis, increasing the need for new therapeutic strategies beyond osimertinib. Frontline osimertinib-based combination strategies (platinum-based chemotherapy and angiogenesis inhibitors) are currently being tested primarily to prevent initial resistance. In the later-line setting after osimertinib, many next-line therapeutic candidates have been actively examined in clinical trials. Notably, several drugs with novel mechanisms of action, such as antibody-drug conjugates and EGFR -MET bispecific antibodies, have shown promising efficacy despite the resistance mechanisms and are close to clinical application. In addition, genotype-based target strategies have been investigated for a better understanding of osimertinib resistance mechanisms based on molecular profiling tests at relapse. The C797S mutation and MET gene alterations are commonly identified following osimertinib resistance, for which targeting strategies are actively tested. This review describes current pharmacotherapeutic strategies for EGFR-mutated non-small cell lung cancer based on the results of clinical trials and the latest published data, broadly grouped into two sections: 1) EGFR TKIs-based combination therapy in the front-line setting and 2) novel therapeutic strategies after osimertinib resistance. The pharmacotherapeutic management of epidermal growth factor receptor-mutated advanced non-small cell lung cancer has been rapidly updated to a new phase with the advent of genomic medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据